Lung cancer is one of the leading causes of cancer-related death globally. Among all the cancers, the number of patients afflicted with lung cancer is the highest, and the number is constantly rising.[1] This international trend of lung cancer is paralleled in India.[2] Lung cancers represent a group of heterogeneous entities both in terms of histology and molecular profile.[3] Histologically, they are categorized into two types: non–small cell lung carcinoma (NSCLC, 85% of all lung cancers) and small cell lung carcinoma (SCLC, 15% of all lung cancers).[3] NSCLCs are typically subdivided into adenocarcinoma, squamous cell carcinoma (SqCC), and large-cell carcinoma.[3] Both NSCLC and SCLC have very low survival rates.[1] Despite recent technological advances in the diagnosis, medical, and surgical treatments, the outcomes remain poor.[4]
The newer molecular diagnostic modalities have made it easier to detect cancer-related driver alterations, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK).[56] Furthermore, accurate staging of cancer is important to plan the treatment for the patients. Recently, an individualized treatment approach, including targeted therapies for driver mutations and immunotherapies, is being used for the patients.[6] However, a comprehensive data on lung cancer in India are lacking.[4]